V.‐P. Harjola

2.6k total citations · 1 hit paper
19 papers, 1.9k citations indexed

About

V.‐P. Harjola is a scholar working on Cardiology and Cardiovascular Medicine, Epidemiology and Emergency Medicine. According to data from OpenAlex, V.‐P. Harjola has authored 19 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Cardiology and Cardiovascular Medicine, 4 papers in Epidemiology and 4 papers in Emergency Medicine. Recurrent topics in V.‐P. Harjola's work include Heart Failure Treatment and Management (5 papers), Cardiac pacing and defibrillation studies (3 papers) and Cardiac Arrest and Resuscitation (3 papers). V.‐P. Harjola is often cited by papers focused on Heart Failure Treatment and Management (5 papers), Cardiac pacing and defibrillation studies (3 papers) and Cardiac Arrest and Resuscitation (3 papers). V.‐P. Harjola collaborates with scholars based in Finland, Germany and Spain. V.‐P. Harjola's co-authors include Markku S. Nieminen, H. Drexler, Luigi Tavazzi, José López‐Sendón, Johan Lassus, Piotr Ponikowski, M. Hochadel, Ferenc Folláth, M Komajda and Kenneth Dickstein and has published in prestigious journals such as Journal of the American College of Cardiology, European Heart Journal and Critical Care.

In The Last Decade

V.‐P. Harjola

17 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population

2006 901 citations Markku S. Nieminen, D L Brutsaert et al. European Heart Journal profile →

Peers

Countries citing papers authored by V.‐P. Harjola

Since Specialization

Citations

This map shows the geographic impact of V.‐P. Harjola's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by V.‐P. Harjola with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites V.‐P. Harjola more than expected).

Fields of papers citing papers by V.‐P. Harjola

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by V.‐P. Harjola. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by V.‐P. Harjola. The network helps show where V.‐P. Harjola may publish in the future.

Co-authorship network of co-authors of V.‐P. Harjola

This figure shows the co-authorship network connecting the top 25 collaborators of V.‐P. Harjola. A scholar is included among the top collaborators of V.‐P. Harjola based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with V.‐P. Harjola. V.‐P. Harjola is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Soluble urokinase-type plasminogen activator receptor improves early risk stratification in cardiogenic shock 2022 ·European Heart Journal Acute Cardiovascular Care ·(unknown), Johan Lassus, Tuukka Tarvasmäki, Jordi Sans‐Roselló, Heli Tolppanen, (unknown), (unknown), (unknown), Marek Banaszewski, José Silva‐Cardoso, John Parissis, Raija Jurkko, Jindřich Špinar, Maaret Castrén, Alexandre Mebazaa, Josep Masip, V.‐P. Harjola, (unknown)	4
2	Levosimendan in Acute and Advanced Heart Failure: an Expert Perspective on Posology and Therapeutic Application 2018 ·Cardiovascular Drugs and Therapy ·Stefaan Bouchez, Francesco Fedele, George Giannakoulas, Finn Gustafsson, V.‐P. Harjola, Kristjan Karason, Matti Kivikko, Dirk von Lewinski, Fabrizio Oliva, Zoltán Papp, John Parissis, Piero Pollesello, Gerhard Pölzl, Carsten Tschöpe	44
3	Cardiogenic shock: current epidemiology and management 2017 ·(unknown), V.‐P. Harjola	9
4	Cystatin C as a marker of acute kidney injury in acute heart failure: definitions and impact on outcomes of the cardiorenal syndrome 2014 ·STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) ·Johan Lassus, Markku S. Nieminen, Keijo Peuhkurinen, Kari Pulkki, Krista Siirilä‐Waris, Reijo Sund, V.‐P. Harjola	0
5	Emergency Medicine in Finland: First Year Experiences of Specialist Training 2014 ·Journal of Academic Emergency Medicine ·(unknown), Ari Palomäki, V.‐P. Harjola, (unknown), (unknown), (unknown)	8
6	Efficacy and Safety of Apixaban in Patients After Cardioversion for Atrial Fibrillation 2013 ·Journal of the American College of Cardiology ·Greg Flaker, Renato D. Lópes, Sana M. Al‐Khatib, Antonio G. Hermosillo, Stefan H. Hohnloser, (unknown), Jun Zhu, Puneet Mohan, David García, Jozef Bartúnek, Dragoş Vinereanu, Steen Husted, V.‐P. Harjola, Mårten Rosenqvist, John H. Alexander, Christopher B. Granger	170
7	High-Sensitivity Troponin T and Risk Stratification in Patients With Atrial Fibrillation During Treatment With Apixaban or Warfarin 2013 ·Journal of the American College of Cardiology ·Ziad Hijazi, Lars Wallentin, Agneta Siegbahn, Ulrika Andersson, John H. Alexander, Dan Atar, Bernard J. Gersh, Michael G. Hanna, V.‐P. Harjola, John D. Horowitz, Steen Husted, Elaine M. Hylek, Renato D. Lópes, John J.V. McMurray, Christopher B. Granger	120
8	Presence of renal failure and anemia in acute heart failure. Evaluation of different regions in EuroHeart Failure SurveyII 2013 ·European Heart Journal ·Jukka Tolonen, Johan Lassus, Tuukka Tarvasmäki, Markku S. Nieminen, V.‐P. Harjola, (unknown)	1
9	Viral encephalitis associated with pandemic 2009 (H1N1) influenza A 2010 ·BMJ Case Reports ·(unknown), Raija Jurkko, K.‐M. KAUKONEN, (unknown), Tom Bäcklund, Johanna Kaartinen, Elina Kolho, V.‐P. Harjola	7
10	Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II 2008 ·European Heart Journal ·Michel Komajda, Olivier Hanon, M. Hochadel, José López‐Sendón, F Follath, Piotr Ponikowski, V.‐P. Harjola, H. Drexler, Kenneth Dickstein, Luigi Tavazzi, Markku S. Nieminen	210
11	Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP 2007 ·European Heart Journal ·Johan Lassus, V.‐P. Harjola, Reijo Sund, Krista Siirilä‐Waris, J. Melin, Keijo Peuhkurinen, Kari Pulkki, Markku S. Nieminen, (unknown)	169
12	EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population breakdown → 2006 ·European Heart Journal ·Markku S. Nieminen, D L Brutsaert, Kenneth Dickstein, H. Drexler, Ferenc Folláth, V.‐P. Harjola, M. Hochadel, M Komajda, Johan Lassus, José López‐Sendón, Piotr Ponikowski, Luigi Tavazzi, (unknown)	901
13	Two cases of pericarditis associated with blood culture-positive meningococcal septicemia 2005 ·European Journal of Clinical Microbiology & Infectious Diseases ·V.‐P. Harjola, Per‐Ola Carlsson, Matti Valtonen	0
14	Observations and warning signs prior to cardiac arrest. Should a medical emergency team intervene earlier? 2005 ·Acta Anaesthesiologica Scandinavica ·Jouni Nurmi, V.‐P. Harjola, Jerry P. Nolan, Maaret Castrén	63
15	Pre-arrest signs in different types of hospitals 2004 ·Critical Care ·Jouni Nurmi, V.‐P. Harjola, Per H. Rosenberg, Maaret Castrén	1
16	STEERING COMMITTEE AND INVESTIGATORS OF THE LEVOSIMENDAN INFUSION VERSUS DOBUTAMINE (LIDO) STUDY. EFFICACY AND SAFETY OF INTRAVENOUS LEVOSIMENDAN COMPARED WITH DOBUTAMINE IN SEVERE LOWOUTPUT HEART FAILURE (THE LIDO STUDY): A RANDOMISED DOUBLEBLIND TRIAL 2002 ·Ferenc Folláth, John G.F. Cleland, H. Just, (unknown), Hasso Scholz, Keijo Peuhkurinen, V.‐P. Harjola, Veselin Mitrović, (unknown), (unknown), Lasse Lehtonen	126
17	Efficacy and safety of intravenous levosimendan in severe low-output heart failure. A randomized, double-blind comparison to dobutamine (The LIDO-Study) 1999 ·Journal of Cardiac Failure ·Ferenc Folláth, (unknown), H Just, (unknown), (unknown), Keijo Peuhkurinen, V.‐P. Harjola, Veselin Mitrović, (unknown), Lasse Lehtonen	3
18	Report of four cases ofYersinia pseudotuberculosis septicemia and a literature review 1995 ·European Journal of Clinical Microbiology & Infectious Diseases ·Päivi Ljungberg, Matti Valtonen, V.‐P. Harjola, (unknown), Martti Vaara	46
19	Association ofStomatococcus mucilaginosus with cholangitis 1994 ·European Journal of Clinical Microbiology & Infectious Diseases ·V.‐P. Harjola, M. Valtonen, Kaarina Sivonen	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact